10x Genomics Q3 2026 net loss narrows 29% to $19.43 million

By Public Technologies
  • 10x Genomics' third-quarter 2026 net loss narrowed 29% year-over-year to $19.4 million, while revenue rose to $150.7 million.
  • Gross margin climbed 8 percentage points to 75% due primarily to lower inventory write-downs and product mix changes.
  • Global commercial shipments of Atera began, and the new Sentira cloud analysis platform was introduced.
  • Full-year 2026 revenue guidance increased to $625 million–$635 million from $610 million–$630 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA90509) on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.